Weiner Daniel, Watnick Suzanne
Department of Medicine, Tufts University, Medford, Massachusetts.
Department of Medicine, Oregon Health and Science University, Portland, Oregon; and
J Am Soc Nephrol. 2017 Jun;28(6):1697-1706. doi: 10.1681/ASN.2016101079. Epub 2017 Mar 15.
The ESRD Quality Incentive Program (QIP) is the first mandatory federal pay for performance program launched on January 1, 2012. The QIP is tied to the ESRD prospective payment system and mandated by the Medicare Improvements for Patients and Providers Act of 2008, which directed the Centers for Medicare and Medicaid Services to expand the payment bundle for renal dialysis services and legislated that payment be tied to quality measures. The QIP links 2% of the payment that a dialysis facility receives for Medicare patients on dialysis to the facility's performance on quality of care measures. Quality measures are evaluated annually for inclusion on the basis of importance, validity, and performance gap. Other quality assessment programs overlap with the QIP; all have substantial effects on provision of care as clinicians, patients, regulators, and dialysis organizations scramble to keep up with the frequent release of wide-ranging regulations. In this review, we provide an overview of quality assessment and quality measures, focusing on the ESRD QIP, its effect on care, and its potential future directions. We conclude that a patient-centered, individualized, and parsimonious approach to quality assessment needs to be maintained to allow the nephrology community to further bridge the quality chasm in dialysis care.
终末期肾病质量激励计划(QIP)是2012年1月1日推出的首个强制性联邦按绩效付费计划。QIP与终末期肾病前瞻性支付系统相关联,并由2008年的《医疗保险改善患者和提供者法案》授权,该法案指示医疗保险和医疗补助服务中心扩大肾透析服务的支付捆绑范围,并立法规定支付与质量指标挂钩。QIP将透析机构从医疗保险患者的透析服务中获得的2%的支付与该机构在护理质量指标方面的表现联系起来。质量指标每年根据重要性、有效性和绩效差距进行评估以确定是否纳入。其他质量评估计划与QIP重叠;随着临床医生、患者、监管机构和透析组织竞相跟上广泛法规的频繁发布,所有这些计划都对护理提供产生了重大影响。在本综述中,我们概述了质量评估和质量指标,重点关注终末期肾病QIP、其对护理的影响及其潜在的未来方向。我们得出结论,需要保持以患者为中心且个性化、简约的质量评估方法,以使肾脏病学界能够进一步弥合透析护理中的质量差距。